

Algorae Pharmaceuticals Limited

ABN: 14 104 028 042
ASX: 1AI
OTCQB: LVCLY

8 November 2023

Section 708A Cleansing Statement

This notice is given by Algorae Pharmaceuticals Limited (Company) under Section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act).

The Company hereby confirms that:

- a) the Company has issued on 8 November 2023:
 - i. 500,000 fully paid ordinary shares at a deemed issue price of \$0.016 per share;
 - ii. 20,000,000 Performance Rights A in accordance with Shareholder Approval;
 - iii. 20,000,000 Performance Rights B in accordance with Shareholder Approval;
 - iv. 20,000,000 Performance Rights C in accordance with Shareholder Approval; and
 - v. 20,000,000 Performance Rights D in accordance with Shareholder Approval.
- b) the shares were issued without disclosure to investors under Part 6D.2 of the Corporations, Act;
- c) As a disclosing entity the company is subject to regular reporting and disclosure obligations;
- d) As at the date of this notice the Company has complied with:
 - i. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - ii. section 674 of the Corporations Act as it applies to the Company; and
- e) as at the date of this notice, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

Yours Sincerely,



Madhukar Bhalla

Company Secretary